XW043FAIntroduction of Non-Chimeric Antigen Receptor T-cell Immune Effector Cell Therapy into Central Vein, Percutaneous Approach, New Technology Group 10
- Billable / Specific Code
XW043FA is a billable ICD-10-PCS procedure code for Introduction of Non-Chimeric Antigen Receptor T-cell Immune Effector Cell Therapy into Central Vein, Percutaneous Approach, New Technology Group 10. It is valid on HIPAA claims for fiscal year 2026 (October 1, 2025 through September 30, 2026) and groups to MS-DRG 018. The root operation Introduction involves putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products. In AHRQ's Clinical Classifications Software (CCSR), this procedure falls under Administration of therapeutic substances, NEC.
Code Identity
PCS Table Breakdown
Each ICD-10-PCS code is built from seven characters, each an axis of the procedure. Hover or tap the icons for the official CMS definitions.
| Position | Designation | Value | Meaning |
|---|---|---|---|
| 1 | Section | X | New Technology |
| 2 | Body System | W | Anatomical Regions |
| 3 | Operation | 0 | Introduction |
| 4 | BodyPart | 4 | Central Vein |
| 5 | Approach | 3 | Percutaneous |
| 6 | Device/Substance/Technology | F | Non-Chimeric Antigen Receptor T-cell Immune Effector Cell Therapy |
| 7 | Qualifier | A | New Technology Group 10 |
Clinical Classification (CCSR)
AHRQ groups XW043FA into these clinical categories.
Code History
Similar Procedure Codes
Questions About XW043FA
Is XW043FA a billable code?
Yes. XW043FA is a complete seven-character ICD-10-PCS code, specific enough to report Introduction of Non-Chimeric Antigen Receptor T-cell Immune Effector Cell Therapy into Central Vein, Percutaneous Approach, New Technology Group 10 on inpatient claims from October 1, 2025 through September 30, 2026.
What do the characters in XW043FA mean?
XW043FA breaks down character by character: the 1st character X is the Section (New Technology); the 2nd character W is the Body System (Anatomical Regions); the 3rd character 0 is the Operation (Introduction); the 4th character 4 is the BodyPart (Central Vein); the 5th character 3 is the Approach (Percutaneous); the 6th character F is the Device/Substance/Technology (Non-Chimeric Antigen Receptor T-cell Immune Effector Cell Therapy); the 7th character A is the Qualifier (New Technology Group 10).
What MS-DRG does XW043FA group to?
On an inpatient stay, Introduction of Non-Chimeric Antigen Receptor T-cell Immune Effector Cell Therapy into Central Vein, Percutaneous Approach, New Technology Group 10 maps to MS-DRG 018 (chimeric Antigen Receptor (CAR) T-Cell and Other Immunotherapies). The MS-DRG sets the fixed Medicare payment for the stay.
